Ozempic Wegovy price cut India deepens as generics shake up market
Synopsis
Ozempic Wegovy price cut India deepens as Novo Nordisk lowers costs to compete with cheaper generics.
The Ozempic Wegovy price cut India has deepened as Novo Nordisk slashed prices by up to 48% to counter a wave of cheaper generics. The move follows the expiry of semaglutide patents and signals intensifying competition in India’s fast-growing diabetes and weight-loss drug market.
Key highlights
- Ozempic Wegovy price cut India up to 48% across doses
- Patent expiry of semaglutide triggers generic competition
- Indian firms launch drugs up to 70% cheaper
- Price war intensifies with Eli Lilly also competing
Novo Nordisk cuts prices again after patent expiry
Novo Nordisk has reduced prices of Ozempic and Wegovy across multiple doses in India.
- Prices have been cut by up to 36% for Ozempic
- Wegovy prices have dropped by up to 48%
- Average reductions stand at 23.8% and 27%, respectively
The cuts come shortly after the patent on semaglutide expired on March 20.
Generic competition drives aggressive pricing strategy
The Ozempic Wegovy price cut India reflects rising pressure from domestic drugmakers.
At least half a dozen Indian companies have entered the market, including:
- Dr. Reddy's
- Zydus Lifesciences
- Sun Pharma
These firms have launched versions priced up to 70% cheaper than branded drugs.
Revised pricing details across key doses
Novo Nordisk has majorly lowered entry-level pricing:
- 0.25 mg weekly dose now costs ₹1,415 (down from ₹2,200–₹2,712)
- 1 mg dose now priced at ₹2,275 after cuts up to 34%
- Wegovy 0.5 mg dose reduced by 41.5% to ₹2,025
These reductions aim to improve affordability and retain market share.
Doctors say pricing could influence patient choices
Healthcare professionals note that pricing remains a key factor.
Some experts believe patients may still prefer branded drugs like Ozempic and Wegovy if the price gap with generics narrows to around 15%.
Additionally, Novo Nordisk highlighted the added cardiovascular benefits of its treatments.
Rivalry with Eli Lilly intensifies in India
Competition is not limited to generics.
Eli Lilly has also expanded aggressively in India. Its drug Mounjaro quickly became one of the country’s top-selling medicines by value after launch.
Thus, global and local players are locked in a pricing and market share battle.
India becomes key battleground for obesity drugs
India’s large diabetic population and rising obesity rates make it a critical market.
The Ozempic Wegovy price cut India signals a broader shift:
- Greater accessibility for patients
- Increased competition driving innovation
- Pressure on margins for global drugmakers
Australia angle: Pricing pressure could ripple globally
For Australia, the developments could have indirect implications:
- Global pricing pressure may influence drug costs in regulated markets
- Increased competition could accelerate access to obesity treatments
- Pharmaceutical firms may adjust pricing strategies across regions
Now what?
The pricing battle is expected to intensify further.
As more generics enter the market:
- Prices could decline further
- Market share will shift rapidly
- Innovation and differentiation will become critical
For now, Novo Nordisk is betting that price cuts and brand trust will help it retain its leadership position.
FAQs
Q1: Why did Novo Nordisk cut prices in India?
To compete with cheaper generics after the semaglutide patent expired.
Q2: How much have prices fallen?
Prices have been reduced by up to 48%, depending on the dose.
Q3: Who are the main competitors?
Indian drugmakers like Dr. Reddy’s, Zydus and Sun Pharma, along with Eli Lilly.
Q4: Will prices fall further?
Prices may decline further as competition increases and more generics enter the market.
Follow Inspirepreneur Magazine for the business news.
I write about markets, money, and the macro forces that move them. Passionate about turning complex economic trends into sharp, easy-to-understand stories. Off the clock, it’s hip hop, rock, reggae -- and a mix of cricket and basketball.
You Might Also Like
Bitcoin ETF Launch: Immediate Impact and Market Responses
Coro Signs Australian Cybersecurity Distribution Deal With Leader
